Equities

Telesis Bio Inc

TBIO:PKC

Telesis Bio Inc

Actions
  • Price (USD)0.97
  • Today's Change0.06 / 6.59%
  • Shares traded3.33k
  • 1 Year change-89.22%
  • Beta1.7480
Data delayed at least 15 minutes, as of Nov 13 2024 20:26 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.

  • Revenue in USD (TTM)16.28m
  • Net income in USD-50.12m
  • Incorporated2011
  • Employees137.00
  • Location
    Telesis Bio Inc10431 Wateridge Circle, Suite 150SAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 228-4115
  • Fax+1 (302) 636-5454
  • Websitehttps://telesisbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nano Mobile Healthcare Inc0.00-5.46m982.13k3.00---------0.2255-0.22550.00-0.01290.00----0.00-10,475.82-----------------0.3173----------------
Remedent Inc1.13m-259.38k999.80k16.00--0.2112--0.8857-0.013-0.0130.05650.23670.14743.452.69---3.247.35-5.2012.9365.3864.60-21.9721.200.2033-0.7720.00---33.63-21.70-140.31------
Escalon Medical Corp11.98m-176.93k1.19m40.00--1.02--0.099-0.0239-0.02391.620.2442.384.276.34299,537.80-2.49-1.31-5.51-2.8842.9543.60-1.05-0.64431.04-5.030.1457---1.634.47-179.87--12.74--
Arch Therapeutics Inc148.17k-12.99m1.25m8.00------8.46-3.69-3.690.0383-2.830.100.0662--18,521.25-828.03-188.28---804.6339.58---8,276.08-26,945.920.0051-1.32----383.83---32.35---21.76--
Catheter Precision Inc436.00k-9.49m1.35m14.00--0.0254--3.09-12.95-12.950.604618.900.01410.55743.8931,142.86-30.71---33.63--92.20---2,176.84--0.098--0.0434--3,057.14---165.67------
Hawkeye Systems Inc0.00-578.72k1.37m44.00---------0.093-0.0930.00-0.30060.00-------117.01-314.04-----------195.39---1.49--------52.81------
Acutus Medical Inc12.16m-5.82m1.64m233.00------0.1352-0.19650.69660.413-0.16390.17911.321.4452,184.55-8.58-46.76-11.07-56.88-13.40-89.12-47.89-773.491.88-3.391.18--136.3627.03-141.35---35.99--
Telesis Bio Inc16.28m-50.12m1.72m137.00------0.1058-29.66-30.689.615.610.19473.153.40118,832.10-57.15---64.21--49.47---293.54--1.72-52.960.356--0.2697---1.14------
Tenon Medical Inc3.37m-13.87m1.87m21.00------0.5532-39.79-39.799.451.760.42522.275.27160,571.40-174.87---495.99--60.32---411.27--1.02--0.00--323.73--17.63------
Nu-Med Plus Inc0.00-112.13k1.97m2.00---------0.0014-0.00140.00-0.00220.00----0.00-471.23-447.69---------------21.34--------3.56------
Tivic Health Systems Inc1.11m-6.75m2.05m9.00--0.4883--1.84-4.33-4.330.54690.67790.23730.915676.76123,666.70-143.94---176.98--27.85---606.47--6.59--0.00---36.09--18.34------
Helius Medical Technologies Inc594.00k-8.84m2.11m22.00--0.2851--3.55-10.68-10.680.50421.980.06060.74864.4827,000.00-90.17-98.37-110.33-143.5712.7937.27-1,487.54-1,580.663.80--0.00---18.176.1437.11---41.95--
Venus Concept Inc69.81m-49.93m2.43m304.00--0.6567--0.0348-8.38-8.3811.920.51030.7511.032.25229,634.90-53.53-32.71-82.19-44.0168.3968.16-71.28-48.501.30-2.750.9133---23.2628.3114.76---35.08--
HeartSciences Inc18.60k-7.29m2.47m15.00--0.4125--132.58-5.65-5.650.00116.550.00350.0092--1,240.00-135.14---193.38--67.31---39,193.76--4.02-20.720.0777--261.17---3.95------
Leafbuyer Technologies Inc5.60m-709.43k2.50m12.00------0.4466-0.0071-0.00710.0562-0.01684.14--51.16466,779.20-52.37-27.14----36.6334.92-12.67-20.65---4.77----10.0325.63-21.23------
Data as of Nov 13 2024. Currency figures normalised to Telesis Bio Inc's reporting currency: US Dollar USD

Institutional shareholders

1.63%Per cent of shares held by top holders
HolderShares% Held
Abaris Investment Management AGas of 31 Dec 202311.95k0.67%
The Vanguard Group, Inc.as of 30 Sep 20246.16k0.35%
Geode Capital Management LLCas of 30 Sep 20244.08k0.23%
Bridgeway Capital Management LLCas of 30 Jun 20243.72k0.21%
UBS Securities LLCas of 30 Jun 20242.46k0.14%
Merrill Lynch, Pierce, Fenner & Smith, Inc. (Invt Mgmt)as of 30 Jun 2024278.000.02%
Dynamic Wealth Strategies LLCas of 30 Jun 2024138.000.01%
Lord, Abbett & Co. LLCas of 30 Jun 2024102.000.01%
Bank of America, NA (Private Banking)as of 30 Jun 202460.000.00%
RBC Dominion Securities, Inc.as of 30 Jun 202424.000.00%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.